JPH0328224B2 - - Google Patents
Info
- Publication number
- JPH0328224B2 JPH0328224B2 JP58148454A JP14845483A JPH0328224B2 JP H0328224 B2 JPH0328224 B2 JP H0328224B2 JP 58148454 A JP58148454 A JP 58148454A JP 14845483 A JP14845483 A JP 14845483A JP H0328224 B2 JPH0328224 B2 JP H0328224B2
- Authority
- JP
- Japan
- Prior art keywords
- urinary catheter
- antibacterial agent
- organic polymer
- sustained release
- polymer elastomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002485 urinary effect Effects 0.000 claims description 42
- 239000003242 anti bacterial agent Substances 0.000 claims description 32
- 229920001971 elastomer Polymers 0.000 claims description 20
- -1 acridine compound Chemical class 0.000 claims description 19
- 239000000806 elastomer Substances 0.000 claims description 17
- 229920000620 organic polymer Polymers 0.000 claims description 16
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 9
- 239000012730 sustained-release form Substances 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 5
- 229920002379 silicone rubber Polymers 0.000 claims description 5
- 239000004945 silicone rubber Substances 0.000 claims description 5
- 239000011247 coating layer Substances 0.000 claims description 4
- 244000043261 Hevea brasiliensis Species 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- NIMNIJHOINCSAH-UHFFFAOYSA-N 1-ethoxyacridine Chemical compound C1=CC=C2C=C3C(OCC)=CC=CC3=NC2=C1 NIMNIJHOINCSAH-UHFFFAOYSA-N 0.000 claims description 2
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001441 aminoacridine Drugs 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims description 2
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 210000001635 urinary tract Anatomy 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920006173 natural rubber latex Polymers 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- SYUWDSSYDVWBGD-UHFFFAOYSA-N 7-ethoxyacridine-3,9-diamine;hydrochloride Chemical compound Cl.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 SYUWDSSYDVWBGD-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- IRIAEXORFWYRCZ-UHFFFAOYSA-N Butylbenzyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001228 polyisocyanate Polymers 0.000 description 2
- 239000005056 polyisocyanate Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- MTZUIIAIAKMWLI-UHFFFAOYSA-N 1,2-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC=C1N=C=O MTZUIIAIAKMWLI-UHFFFAOYSA-N 0.000 description 1
- ZTNJGMFHJYGMDR-UHFFFAOYSA-N 1,2-diisocyanatoethane Chemical compound O=C=NCCN=C=O ZTNJGMFHJYGMDR-UHFFFAOYSA-N 0.000 description 1
- ZXHZWRZAWJVPIC-UHFFFAOYSA-N 1,2-diisocyanatonaphthalene Chemical compound C1=CC=CC2=C(N=C=O)C(N=C=O)=CC=C21 ZXHZWRZAWJVPIC-UHFFFAOYSA-N 0.000 description 1
- PRBHEGAFLDMLAL-UHFFFAOYSA-N 1,5-Hexadiene Natural products CC=CCC=C PRBHEGAFLDMLAL-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- BAZVBVCLLGYUFS-UHFFFAOYSA-N 1-o-butyl 2-o-dodecyl benzene-1,2-dicarboxylate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC BAZVBVCLLGYUFS-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- YEVQZPWSVWZAOB-UHFFFAOYSA-N 2-(bromomethyl)-1-iodo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(I)C(CBr)=C1 YEVQZPWSVWZAOB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GHCKERHPOQWERJ-UHFFFAOYSA-N 3-aminoacridine Chemical compound C1=CC=CC2=NC3=CC(N)=CC=C3C=C21 GHCKERHPOQWERJ-UHFFFAOYSA-N 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 244000286663 Ficus elastica Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- JCELWOGDGMAGGN-UHFFFAOYSA-N N=C=O.N=C=O.C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound N=C=O.N=C=O.C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 JCELWOGDGMAGGN-UHFFFAOYSA-N 0.000 description 1
- MRWSBLWWDRNONW-UHFFFAOYSA-N P(=O)(OCCCC)(OC1(C(C=CC=C1)C)C)OC1(C(C=CC=C1)C)C Chemical compound P(=O)(OCCCC)(OC1(C(C=CC=C1)C)C)OC1(C(C=CC=C1)C)C MRWSBLWWDRNONW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WSFHCKWLECYVBS-UHFFFAOYSA-N acridine-3,6-diamine;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WSFHCKWLECYVBS-UHFFFAOYSA-N 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BEWFIPLBFJGWSR-UHFFFAOYSA-N butyl 12-acetyloxyoctadec-9-enoate Chemical compound CCCCCCC(OC(C)=O)CC=CCCCCCCCC(=O)OCCCC BEWFIPLBFJGWSR-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PDXRQENMIVHKPI-UHFFFAOYSA-N cyclohexane-1,1-diol Chemical compound OC1(O)CCCCC1 PDXRQENMIVHKPI-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- PUFGCEQWYLJYNJ-UHFFFAOYSA-N didodecyl benzene-1,2-dicarboxylate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCCCC PUFGCEQWYLJYNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- XWVQUJDBOICHGH-UHFFFAOYSA-N dioctyl nonanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCC(=O)OCCCCCCCC XWVQUJDBOICHGH-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000005053 encephalomalacia Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GEAWFZNTIFJMHR-UHFFFAOYSA-N hepta-1,6-diene Chemical compound C=CCCCC=C GEAWFZNTIFJMHR-UHFFFAOYSA-N 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical compound C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- LADVLFVCTCHOAI-UHFFFAOYSA-N isocyanic acid;toluene Chemical compound N=C=O.CC1=CC=CC=C1 LADVLFVCTCHOAI-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920006295 polythiol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BPJZKLBPJBMLQG-KWRJMZDGSA-N propanoyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OC(=O)CC BPJZKLBPJBMLQG-KWRJMZDGSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000004537 pyelitis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical class OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- DUBNHZYBDBBJHD-UHFFFAOYSA-L ziram Chemical compound [Zn+2].CN(C)C([S-])=S.CN(C)C([S-])=S DUBNHZYBDBBJHD-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
【発明の詳細な説明】
本発明は導尿カテーテルに関するものであり、
さらに詳しくは抗菌物質徐放性能を有する導尿カ
テーテルに関するものである。
脊髄損傷,脳出血,脳軟化症あるいは手術後の
患者においては、排尿困難,尿失禁などの症状を
伴うことが多い。このような場合は円滑な尿路を
確保し、腎機能の維持や改善を促すかあるいは尿
の漏出を防止するといつた意味で導尿カテーテル
が広く用されている。しかし,導尿カテーテルは
長期間尿路内に留置しておくため、このカテーテ
ルの管内外を通じて細菌が侵入し、尿道炎、膀
胱,腎う炎等の感染が高頻度に発生することが知
られている。この対策として従来は膀胱の洗浄や
殺菌剤の注入あるいは抗生物質をはじめとする抗
菌物質の予防的投与も行われているが、これらは
余分な操作を必要とするばかりでなく効果が不確
実である。このため、最近では導尿カテーテル設
置局所での細菌感染を根本的に防止するために、
抗菌剤が局所において一定速度で長期間徐放され
るタイプの導尿カテーテルの出現が強く望まれて
いる。
従来、医薬あるいは薬学領域における薬剤のコ
ントロールリリース技術に関しては、例えば化学
工学、第45巻、第7号、441頁(1981)の総説に
記載されているように(1)マトリツクス構造のポリ
マーや細孔質内に活性物質を分散させたもの、(2)
薄膜により活性物質をマイクロカプセル化したも
の、(3)浸透圧によるオスモテイツクポンプを利用
したもの及び(4)活性物質を含むココア物質の外部
を侵食性物質でコーテイングしたものの4種類に
大別される。これらのうち、薬剤の時間的経過に
伴う放出量変化がない一定速度の放出、すなわち
ゼロ・オーダー・リリース(Zero order relese)
は(2)、(3)、(4)においては可能であるが、一般的に
は特別な工夫や高度な技術が要求される。一方、
(1)のポリマーマトリツクス内に薬剤を分散させた
ものは製造が容易であるために古くから種々の形
態で実用化されているが、ゼロ・オーダー・リリ
ースは不可能であり、そのような例は今までにほ
とんど知られていない。すなわち(1)においては、
一般的に初期に異常な大量放出が認められ、その
後、急激に放出量が減少し、以後、漸減する傾向
が認められる。
ところで導尿カテーテルにおいてもその体内留
置期間中において、抗菌剤が一定速度で放出され
続けることが重要であることは言うまでもない。
すなわち、抗菌剤が各種の細菌に対し一定の殺菌
効果を有するためには、いわゆる最小(発育)阻
止濃度(Minimal Inhibitory Concentration,
以下、MICと称す。)以上の抗菌剤が、その使用
期間中において徐放され続けることが重要であ
り、一方、MIC以上の抗菌剤の異常放出は経済
的に不利であるばかりでなく、尿路や膀胱内の粘
膜に対し副作用としての炎症をもたらすことにな
り好ましくない。
以上のような技術的背景を踏まえた上で、本発
明者らは工業的に製造の容易なマトリツスとして
の有機高分子系エラストマーを主成分とする導尿
カテーテルの表面又は/及び内部に抗菌剤を分散
させた系について、ゼロ・オーダー・リリースが
達成されないものかどうか鋭意検討した結果、驚
くべきことに抗菌剤として難水溶性のアクリジン
化合物又はその塩が有機高分子系エラストマー中
に分散された系において実質的にゼロ・オーダ
ー・リリースが達成されることを見い出し、本発
明に到達したものである。
すなわち本発明は、有機高分子系エラストマー
を主成分とする導尿カテーテルにおいて、該有機
高分子系エラストマーのマトリツクス内に難水溶
性のアクリジン化合物又はこの塩が分散されてい
ることを特徴とする抗菌剤徐放性導尿カテーテル
である。
本発明は、特別な工夫や高度な技術を要するこ
となく製造方法の極めて容易なポリマーマトリツ
クスとしての有機高分子系エラストマー内に難水
溶性のアクリジン化合物又はその塩を分散させた
だけで、実質的にゼロ・オーダー・リリースを実
現した導尿カテーテルを提供するものであり、そ
の工業的意義は極めて大きい。本発明において実
質的にゼロ・オーダー・リリースが達成された理
由については明らかではないが、本発明における
難水溶性のアクリジン化合物又はその塩の水に対
する溶解度が低いことや素材マトリツクスとの相
互作用が、相乗的に作用したためと考えられる。
すなわち本発明におけるアクリジン化合物はその
化学構造において極性基としてのカチオン基とと
もに、疎水性環状構造もつことを特徴とするが、
これらが水中に浸漬した場合水や疎水性の有機高
分子系エラストマー材料との相互作用において有
利に作用したことが考えられる。
本発明における有機高分子系エラストマーと
は、常温付近でゴム状弾性を有するものであり、
例えば天然ゴム、合成ゴム、シリコンゴム、ポリ
ウレタン、軟質ポリ塩化ビニル等が含まれる。こ
こで天然ゴムとは、ゴム植物の樹皮に切付を行つ
た時に流れ出る種々の有機物及び無機物を含有し
た水溶液を分散媒体とし、ゴム分を分散質とし、
必要に応じてPH調整剤、加硫剤、加硫促進剤、軟
化剤、充填剤、老化防止剤等を配合したものを意
味する。合成ゴムとしては、例えばブタジエン、
イソプレン、1,3−ペンタジエン、1,5−ヘ
キサジエン、1,6−ヘプタジエン、クロロプレ
ン等のジエン系モノマーの単一重合体あるいはそ
の共重合体があげられる。シリコンゴムとは高重
合度のオルガノポリシロキサンに、必要に応じ
て、例えば無機充填剤、分散促進剤、加硫剤等を
配合したものを意味し、オルガノポリシロキサン
としては、例えばジメチルポリシロキサン、メチ
ルフエニルポリヒシロキサン、メチルビニルポリ
シロキサン、フロロアルキルメチルポリシロキサ
ン等があげられる。また、ポリウレタンとは主鎖
の繰り返し単位中にポリイソシアナートとポリオ
ールからなるウレタン結合を有するエラストマー
を意味する。ポリイソシアナートとしては、例え
ばトルエンジイソシアナート、キシレンジイソシ
アナート、ナフタレンジイソシアナート、ジフエ
ニルメタンジイソシアナート、フエニレンジイソ
シアナート、エチレンジイソシアナート、シクロ
ヘキシレンジイソシアナート、トリフエニルメタ
ントリイソシアナート、トルエントリイソシアナ
ート等があげられ、ポリオールとしては、例えば
エチレングリコール、プロピレングリコール、ブ
チレングリコール、ジエチレングリコール、シク
ロヘキサンジオール、ペンタエリスリトール、グ
リセリン、1,1,1−トリメチロールプロパン
等のポリオール、ポリエチレングリコール、ポリ
プロピレングリコール、ポリテトラメチレングリ
コール、ポリエチレングリコール/ポリプロピレ
ングリコール共重合体等のポリエーテルポリオー
ル等があげられる。また、ポリオールには、例え
ばコハク酸、グルタル酸、アビピン酸、セバシン
酸、イソフタル酸、フタル酸、テレフタル酸等の
ジカルボン酸とエチレングリコールやプロピレン
グリコール等の縮合によつて得られる両末端に水
酸基を有するポリエステル等も含まれる。さら
に、これらのポリオールの一部をポリアミン、ポ
リチオール、ポリカルボン酸等の他の活性水素化
合物に置き換えたものも含まれる。また、軟質ポ
リ塩化ビニルとしては、例えばポリ塩化ビニル単
独重合体に可塑剤を配合したものあるいは他成分
との共重合により内部可塑化したものがあげられ
る。前者の可塑剤としては、ジブチルフタレー
ト、ジ−2−エチルヘキシルフタレート、ジオク
チルフタレート、ブチルラウリルフタレート、ジ
ラウリルフタレート、ブチルベンジルフタレート
等のフタル酸エステル類、ジオクチルアジペー
ト、ジオクチルアゼレート、ジオクチルセバケー
ト等の直鎖二塩基酸エステル類、トリクレジルホ
スフエート、トリキシレニホスフエート、モノブ
チルジキシレニルホスフエート、トリオクチルホ
スフエート等のリン酸エステル類、メチルアセチ
ルリシノレート、ブチルアセチルリシノレート等
のヒマシ油誘導体、大豆油等の不飽和脂肪酸をエ
ポキシ化したエポキシ化植物油、炭素数6〜10の
脂肪酸のトリ又はテトラエチレングリコールエス
テル、ブチルフタルブチルグリコレート等のエチ
レングリコール誘導体、平均分子量、1000〜3000
の粘調な低級ポリエステル系可塑剤等があげられ
る。また、後者の塩化ビニルの共重合モノマーと
しては、例えば酢酸ビニル、塩化ビニリデン、ア
クリル酸又はメタクリル酸及びそのエステル、マ
レイン酸とそのエステル、アクリロニトリル等が
あげられる。
本発明におけるアクリジン化合物とは、下記の
アクリジン骨格を有する化合物でああり、「大有
機化学」第16巻
286〜326頁(朝倉書点、昭和34年)に種々の誘導
体が記載されている。かかるアクリジン化合物の
好適な具体例として9−アミノアクリジン、3,
6−アミノアクリジン、6,9−ジアミノ−2−
エトキシアクリジン等があげられ、これらは広範
囲の微生物に対し強力な殺菌力を有し、かつ人体
に対する毒性も低いところから、今日医療、衛生
並びに食品業界においても最も広く使用されてい
る殺菌消毒剤の一つであり、本発明においても特
に好ましく用いられる。
本発明にいう難水溶性とは、20℃における
100gの蒸留水に対する溶解度が0.001〜1.0g、好
ましくは0.005〜0.7gの範囲のものを指す。水に
対する溶解度が0.001g未満では局所での放出量が
低く殺菌剤としての効力が減退する。一方、1.0g
をこえるものでは初期の異常放出が認められ、ゼ
ロ・オーダー・リリースが実現されなくなる。
本発明の導尿カテーテルにおける難水溶性のア
クリジン化合物又はその塩の含有量はその目的と
するところにより異なるが、好ましくは0.01〜
30wt%、より好ましくは0.1〜10wt%である。
本発明の抗菌剤徐放性導尿カテーテルは従来公
知の製造方法を利用することにより容易に製造す
ることができる。例えば天然ゴムラテツクス浸漬
液中に浸漬型を浸漬して導尿カテーテルを製造す
る場合には、少なくとも一回は上記抗菌剤が均一
に分散された浸漬液中に浸漬し、その後、熱処理
を施すことにより製造することができる。また、
シリコンゴムのように押出し成型法や圧縮成型法
により製造する場合には、成型機にかける前の素
練りの段階で上記抗菌剤を添加し、その後、通常
の方法で成形、加硫して製造することができる。
なお、上記抗菌剤の添加に際しては従来用いられ
ている分散剤あるいは分散促進剤を用いることに
より、より均一な安定した抗菌剤分散組成物を得
ることが可能である。例えば天然ゴムラテツクス
への抗菌剤の添加に際しては、あらかじめ抗菌剤
を、界面活性剤や増粘剤や保護コロイドとともに
ボールミル内で摩砕しながら均一なペースト状水
分散物とした後に添加することが好ましい。また
シシリコンゴムへの添加に際してはシリコンレジ
ン、アルコキシシラン及びシロキサン、ヒドロキ
シシラン及びシロキサン、有機酸エステル、多価
アルコール等の分散促進剤を利用することにより
分散性が向上する。
以上のように本発明は有機高分子系エラストマ
ーを主成分とする導尿カテーテルに難水溶性のア
クリジン化合物又はその塩が含まれているもので
あるが、上記導尿カテーテルが体内留置された場
合、尿路粘膜との接触面である外表面での抗菌剤
の高濃度放出に伴う尿路粘膜の炎症を防止するた
めに、上記抗菌剤を含まない有機高分子系エラス
テトマーのみよりなる薄い被覆層を外表面に設け
ることが好ましい。また、上記導尿カテーテルの
尿の排出路である内表面において、抗菌剤が溶出
した後の凹面に尿中の塩やカルシウム成分が沈着
し、ひいては尿路の閉塞をきたすような事態をさ
けるために、上記抗菌剤を含まない有機高分子系
エラストマーよりなる薄い被覆層を内表面に設け
ることが好ましい。さらに、上記導尿カテーテル
において抗菌剤の溶出に伴う力学的強度の低下、
例えばバルーンの破裂等の事態をさけるために、
上記導尿カテーテルの外表面と内表面の間、例え
ば中間に抗菌剤を含まない有機高分子系エラスト
マーのみよりなる層を設けることも好ましいこと
である。
以下具体的な実施例を示し本発明を詳述する。
なお、例中の「部」は「重量部」を意味する。
実施例 1
6,9−ジアミノ−2−エトキシアクリジンの
塩酸塩100部、蒸留水100部をボールミルにて100
時間かけて摩砕分散し、抗菌剤分散液(以下A液
と称す)。を調製した。一方、固形分濃度が約
50wt%の天然ゴムラテツクス100部にジメチルジ
チオカルバミン酸亜鉛0.3部、硫黄1.5部、亜鉛華
3部及びステアリン酸1.2部を加えた配合ラテツ
クス液(以下B液と称す。)を調製した。次いで
B液100部に対しA液を10部加え浸漬液(以下C
液と称す。)を調製した。
次に、導尿カテーテル用浸漬型を上記浸漬液中
に浸漬したのち引き上げ、乾燥(80℃×5分)す
るという操作を5回繰り返し、最後に70℃で10時
間熱処理を施して乾燥上り重量約12gの導尿カテ
ーテルを作製した。
得られた導尿カテーテルを、37℃の試験尿100
ml中に浸漬し、1日経過後、検定菌として
Bacillus Subtilis ATCC 6633(培地
NUTRIENT AGAR)を用い、円筒平板法(デ
イスク法)にて抗菌活性テストを行い、そこに生
じた阻止円の大きさからあらかじめ求めておいて
検量線より放出された抗菌剤濃度を求めた。さら
に試験尿を1日ごとに新しい試験尿に取り替えて
同様の活性テストを14回まで繰り返した。このよ
うにして得られた結果を表1に示す。
また、作製した導尿カテーテルを5人の患者に
ついて臨床応用したところ、2週間の体内留置に
おいても全例について尿路感染は認められなかつ
た。また使用に伴う不快感や尿路粘膜の炎症等も
特に認められなかつた。
比較例 1
A液を使用せずに、B液のみからなる浸漬液を
用いたほかは実施例1と同様にして導尿カテーテ
ルを作製した。
この導尿カテーテルを、実施例1と同様に5人
の患者に臨床応用したところ、2人の患者につい
ては3日目において1人については4日目におい
て他の1人については5日目において、それぞれ
尿路感染が認められた。
実施例 2
B液100部に対するA液の添加量を16部とした
以外は実施例1と同様にして導尿カテーテルを
得、実施例1と同じ抗菌活性テストを行つた。得
られた結果を表−1に示す。
実施例 3
6,9−ジアミノ−2−エトキシアクリジンの
塩酸塩にかえて3,6−ジアミノアクリジンの硫
酸塩を使用した以外は実施例1と同様にして導尿
カテーテルを得、実施例1と同じ抗菌活性テスト
を行つた。得れた結果を表−1に示す。
実施例 4
メチルビニルポリシロキサン生ゴム100部にシ
リカ微粉末20部、過酸化ベンゾイル2部及び9−
アミノアクリジンの硫酸塩25部を加え、ゴム用ロ
ール機でよく素練りしたものを押出し成型及び圧
縮成型して導尿カテーテルを作製した。
得られた導尿カテーテルについて実施例1と同
じ抗菌活性テストを行つた。その結果を表−1に
示す。
実施例 5
実施例1において作製した導尿カテーテルの内
表面及び外表面上にB液のみからなる厚さ約30μ
の抗菌剤を含まない被覆層を設けた。この導尿カ
テーテルについて実施例1と同様にして抗菌剤の
放出挙動を検討したところ表−1の結果を得た。
【表】DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a urinary catheter,
More specifically, the present invention relates to a urinary catheter having the ability to release antibacterial substances in a sustained manner. Patients with spinal cord injury, cerebral hemorrhage, encephalomalacia, or surgery are often accompanied by symptoms such as difficulty urinating and urinary incontinence. In such cases, urinary catheters are widely used to ensure a smooth urinary tract, promote maintenance or improvement of renal function, or prevent urine leakage. However, because urinary catheters are left in the urinary tract for long periods of time, bacteria can enter inside and outside the catheter, leading to frequent infections such as urethritis, bladder infection, and pyelitis. ing. Conventional countermeasures have included cleaning the bladder, injecting disinfectants, and administering prophylactic antibacterial substances such as antibiotics, but these not only require extra procedures but also have uncertain effects. be. For this reason, recently, in order to fundamentally prevent bacterial infection at the site where the urinary catheter is installed,
There is a strong desire for a type of urinary catheter that can locally release antibacterial agents at a constant rate over a long period of time. Conventionally, regarding controlled release technology for drugs in the field of medicine and pharmacy, for example, as described in the review of Kagaku Kogaku, Vol. 45, No. 7, p. 441 (1981), (1) matrix-structured polymers and fine particles have been used. active substances dispersed within pores, (2)
There are four types: (3) those that use an osmotic pump using osmotic pressure, and (4) those that coat the outside of the cocoa material containing the active substance with an erodible substance. be done. Among these, release at a constant rate with no change in release amount over time, i.e. zero order release.
Although it is possible in (2), (3), and (4), special ingenuity and advanced technology are generally required. on the other hand,
(1) Drugs dispersed within polymer matrices are easy to manufacture and have been in practical use in various forms for a long time, but zero-order release is impossible, and such Few examples are known to date. In other words, in (1),
Generally, an abnormally large amount of release is observed at the beginning, and then the amount released decreases rapidly, and thereafter there is a tendency for it to gradually decrease. By the way, it goes without saying that it is important for a urinary catheter to continue releasing the antibacterial agent at a constant rate while the catheter is indwelling in the body.
In other words, in order for an antibacterial agent to have a certain bactericidal effect on various types of bacteria, the so-called minimum inhibitory concentration (minimal inhibitory concentration) is required.
Hereinafter referred to as MIC. ) It is important that the above antibacterial agents continue to be released in a sustained manner during the period of use. On the other hand, abnormal release of antibacterial agents above the MIC is not only economically disadvantageous, but also causes damage to the mucous membranes in the urinary tract and bladder. This is not preferable because it causes inflammation as a side effect. Based on the above technical background, the present inventors applied an antibacterial agent to the surface and/or inside of a urinary catheter whose main component is an organic polymer elastomer as a matrix that is easy to manufacture industrially. As a result of intensive investigation into whether or not zero-order release could be achieved in a system in which antibacterial agents are dispersed, it was surprisingly discovered that a poorly water-soluble acridine compound or its salt as an antibacterial agent was dispersed in an organic polymer elastomer. The present invention was achieved based on the discovery that substantially zero-order release can be achieved in the system. That is, the present invention provides a urinary catheter mainly composed of an organic polymer elastomer, which is an antibacterial catheter characterized in that a sparingly water-soluble acridine compound or a salt thereof is dispersed in a matrix of the organic polymer elastomer. This is a sustained release urinary catheter. The present invention can be achieved by simply dispersing a poorly water-soluble acridine compound or its salt in an organic polymer elastomer as a polymer matrix, which is extremely easy to manufacture without requiring special devices or advanced techniques. This provides a urinary catheter that achieves zero-order release, and its industrial significance is extremely large. The reason why substantially zero-order release was achieved in the present invention is not clear, but the reason is that the poorly water-soluble acridine compound or its salt in the present invention has low solubility in water and interaction with the material matrix. This is thought to be due to a synergistic effect.
That is, the acridine compound in the present invention is characterized by having a cationic group as a polar group and a hydrophobic cyclic structure in its chemical structure.
It is thought that when these were immersed in water, they had an advantageous effect on the interaction with water and the hydrophobic organic polymer elastomer material. The organic polymer elastomer in the present invention has rubber-like elasticity at around room temperature,
Examples include natural rubber, synthetic rubber, silicone rubber, polyurethane, soft polyvinyl chloride, and the like. Here, natural rubber is made by using an aqueous solution containing various organic and inorganic substances that flows out when cutting the bark of a rubber plant as a dispersion medium, and using the rubber component as a dispersoid.
This means a product containing a PH adjuster, vulcanizing agent, vulcanization accelerator, softener, filler, anti-aging agent, etc. as necessary. Examples of synthetic rubber include butadiene,
Examples include homopolymers of diene monomers such as isoprene, 1,3-pentadiene, 1,5-hexadiene, 1,6-heptadiene, and chloroprene, or copolymers thereof. Silicone rubber refers to organopolysiloxane with a high degree of polymerization mixed with, for example, an inorganic filler, a dispersion accelerator, a vulcanizing agent, etc. as necessary. Examples of organopolysiloxane include dimethylpolysiloxane, Examples include methylphenylpolyhsiloxane, methylvinylpolysiloxane, and fluoroalkylmethylpolysiloxane. Moreover, polyurethane means an elastomer having urethane bonds made of polyisocyanate and polyol in the repeating unit of the main chain. Examples of the polyisocyanate include toluene diisocyanate, xylene diisocyanate, naphthalene diisocyanate, diphenylmethane diisocyanate, phenylene diisocyanate, ethylene diisocyanate, cyclohexylene diisocyanate, and triphenylmethane diisocyanate. Isocyanate, toluene isocyanate, etc., and examples of polyols include polyols such as ethylene glycol, propylene glycol, butylene glycol, diethylene glycol, cyclohexanediol, pentaerythritol, glycerin, 1,1,1-trimethylolpropane, and polyethylene. Examples include polyether polyols such as glycol, polypropylene glycol, polytetramethylene glycol, and polyethylene glycol/polypropylene glycol copolymers. Polyols also have hydroxyl groups at both ends obtained by condensing dicarboxylic acids such as succinic acid, glutaric acid, abipic acid, sebacic acid, isophthalic acid, phthalic acid, and terephthalic acid with ethylene glycol or propylene glycol. It also includes polyester and the like. Furthermore, those in which a part of these polyols are replaced with other active hydrogen compounds such as polyamines, polythiols, and polycarboxylic acids are also included. Examples of soft polyvinyl chloride include polyvinyl chloride homopolymer blended with a plasticizer or internally plasticized by copolymerization with other components. The former plasticizers include phthalic acid esters such as dibutyl phthalate, di-2-ethylhexyl phthalate, dioctyl phthalate, butyl lauryl phthalate, dilauryl phthalate, butyl benzyl phthalate, dioctyl adipate, dioctyl azelate, dioctyl sebacate, etc. Linear dibasic acid esters, phosphate esters such as tricresyl phosphate, tricylene phosphate, monobutyl dixylenyl phosphate, trioctyl phosphate, methyl acetyl ricinoleate, butylacetyl ricinoleate, etc. Castor oil derivatives, epoxidized vegetable oils obtained by epoxidizing unsaturated fatty acids such as soybean oil, tri- or tetraethylene glycol esters of fatty acids having 6 to 10 carbon atoms, ethylene glycol derivatives such as butylphthalbutyl glycolate, average molecular weight, 1000 to 3000
Examples include viscous lower polyester plasticizers. Examples of the latter vinyl chloride copolymer monomer include vinyl acetate, vinylidene chloride, acrylic acid or methacrylic acid and its ester, maleic acid and its ester, acrylonitrile, and the like. The acridine compound in the present invention is a compound having the following acridine skeleton, and is a compound having the following acridine skeleton. Various derivatives are described on pages 286 to 326 (Asakura Shoten, 1960). Preferred specific examples of such acridine compounds include 9-aminoacridine, 3,
6-aminoacridine, 6,9-diamino-2-
These include ethoxyacridine, which has strong sterilizing power against a wide range of microorganisms and low toxicity to the human body, so it is one of the most widely used sterilizing agents in the medical, hygiene, and food industries today. It is one of these, and is particularly preferably used in the present invention. Poor water solubility as used in the present invention refers to
The solubility in 100 g of distilled water is 0.001 to 1.0 g, preferably 0.005 to 0.7 g. If the solubility in water is less than 0.001 g, the amount of local release is low and the efficacy as a bactericidal agent is reduced. On the other hand, 1.0g
If the amount exceeds 100%, initial abnormal release will be observed and zero-order release will not be achieved. The content of the poorly water-soluble acridine compound or its salt in the urinary catheter of the present invention varies depending on the intended purpose, but is preferably 0.01 to 0.01.
It is 30wt%, more preferably 0.1 to 10wt%. The antibacterial agent sustained release urinary catheter of the present invention can be easily manufactured using conventionally known manufacturing methods. For example, when manufacturing a urinary catheter by immersing a dipping mold in a natural rubber latex dipping solution, it is immersed at least once in a dipping solution in which the antibacterial agent is uniformly dispersed, and then heat-treated. can be manufactured. Also,
When manufacturing by extrusion molding or compression molding, such as silicone rubber, the above antibacterial agent is added during the mastication stage before being applied to the molding machine, and then molded and vulcanized in the usual manner. can do.
In addition, when adding the above-mentioned antibacterial agent, it is possible to obtain a more uniform and stable antibacterial agent dispersion composition by using a conventionally used dispersant or dispersion promoter. For example, when adding an antibacterial agent to natural rubber latex, it is preferable to grind the antibacterial agent together with a surfactant, thickener, and protective colloid in a ball mill to form a uniform paste-like aqueous dispersion before adding it. . When added to silicone rubber, dispersibility can be improved by using a dispersion accelerator such as silicone resin, alkoxysilane and siloxane, hydroxysilane and siloxane, organic acid ester, and polyhydric alcohol. As described above, the present invention is directed to a urinary catheter mainly composed of an organic polymer elastomer containing a poorly water-soluble acridine compound or its salt; however, when the urinary catheter is placed in the body, In order to prevent inflammation of the urinary tract mucosa caused by the release of high concentrations of antibacterial agents on the outer surface, which is the surface that comes into contact with the urinary tract mucosa, a thin coating layer made only of an organic polymer elastomer that does not contain the above antibacterial agent is used. is preferably provided on the outer surface. Furthermore, on the inner surface of the urinary catheter, which is the urine drainage path, after the antibacterial agent has been eluted, salt and calcium components in the urine are deposited on the concave surface, and this is to prevent the situation where the salt and calcium components in the urine are deposited, which may lead to obstruction of the urinary tract. In addition, it is preferable to provide a thin coating layer made of an organic polymer elastomer containing no antibacterial agent on the inner surface. Furthermore, the mechanical strength of the urinary catheter decreases due to the elution of the antibacterial agent,
For example, to avoid situations such as balloon bursting,
It is also preferable to provide a layer consisting only of an organic polymer elastomer containing no antibacterial agent between the outer surface and the inner surface of the urinary catheter, for example in the middle. The present invention will be described in detail below with reference to specific examples.
Note that "parts" in the examples mean "parts by weight." Example 1 100 parts of 6,9-diamino-2-ethoxyacridine hydrochloride and 100 parts of distilled water were mixed in a ball mill to 100 parts
The antibacterial agent dispersion liquid (hereinafter referred to as liquid A) is obtained by grinding and dispersing it over time. was prepared. On the other hand, the solid content concentration is approx.
A blended latex liquid (hereinafter referred to as liquid B) was prepared by adding 0.3 parts of zinc dimethyldithiocarbamate, 1.5 parts of sulfur, 3 parts of zinc white, and 1.2 parts of stearic acid to 100 parts of 50 wt% natural rubber latex. Next, add 10 parts of liquid A to 100 parts of liquid B to make the immersion liquid (hereinafter referred to as C).
It is called liquid. ) was prepared. Next, the immersion type for urinary catheter was immersed in the above-mentioned immersion liquid, then pulled out and dried (80℃ x 5 minutes), which was repeated 5 times.Finally, heat treatment was performed at 70℃ for 10 hours, resulting in a dry weight. A urinary catheter weighing approximately 12 g was prepared. The obtained urinary catheter was heated to 37°C with 100% test urine.
ml, and after 1 day, use it as a test bacterium.
Bacillus Subtilis ATCC 6633 (medium
An antibacterial activity test was conducted using the cylinder plate method (disk method) using a NUTRIENT AGAR, and the concentration of the released antibacterial agent was determined from the size of the inhibition circle generated in advance from the calibration curve. Furthermore, the test urine was replaced with fresh test urine every day and the same activity test was repeated up to 14 times. The results thus obtained are shown in Table 1. Furthermore, when the fabricated urinary catheter was applied clinically to five patients, no urinary tract infection was observed in any of the cases even after indwelling in the body for two weeks. Furthermore, no discomfort or inflammation of the urinary tract mucosa was observed during use. Comparative Example 1 A urinary catheter was produced in the same manner as in Example 1, except that an immersion liquid consisting only of liquid B was used instead of liquid A. When this urinary catheter was clinically applied to five patients in the same manner as in Example 1, two patients were treated on the third day, one on the fourth day, and the other on the fifth day. , each of whom had a urinary tract infection. Example 2 A urinary catheter was obtained in the same manner as in Example 1, except that 16 parts of liquid A was added to 100 parts of liquid B, and the same antibacterial activity test as in Example 1 was conducted. The results obtained are shown in Table-1. Example 3 A urinary catheter was obtained in the same manner as in Example 1 except that 3,6-diaminoacridine sulfate was used instead of 6,9-diamino-2-ethoxyacridine hydrochloride, and a urinary catheter was obtained in the same manner as in Example 1. The same antibacterial activity test was performed. The results obtained are shown in Table-1. Example 4 100 parts of methylvinyl polysiloxane raw rubber, 20 parts of silica fine powder, 2 parts of benzoyl peroxide and 9-
A urinary catheter was prepared by adding 25 parts of aminoacridine sulfate and thoroughly masticating the mixture using a rubber roll machine, followed by extrusion molding and compression molding. The same antibacterial activity test as in Example 1 was conducted on the obtained urinary catheter. The results are shown in Table-1. Example 5 On the inner and outer surfaces of the urinary catheter produced in Example 1, a thickness of approximately 30 μm consisting only of liquid B was coated.
A coating layer containing no antibacterial agent was provided. Regarding this urinary catheter, the antibacterial agent release behavior was examined in the same manner as in Example 1, and the results shown in Table 1 were obtained. 【table】
Claims (1)
尿カテーテルにおいて、該有機高分子系エラスト
マーのマトリツクス内に難水溶性のアクリジン化
合物又はその塩が分散されていることを特徴とす
る抗菌剤徐放性導尿カテーテル。 2、導尿カテーテルの外表面又は/及び内表面に
有機高分子系エラストマーのみからなる薄い被覆
層が設けられている特許請求の範囲第1項記載の
抗菌剤徐放性導尿カテーテル。 3 導尿カテーテルの外表面と内表面の間に有機
高分子系エラストマーのみからなる層が設けられ
ている特許請求の範囲第1項記載の抗菌剤徐放性
導尿カテーテル。 4 有機高分子系エラストマーが天然ゴム又はシ
リコンゴムである特許請求の範囲第1項記載の抗
菌剤徐放性導尿カテーテル。 5 アクリジン化合物が9−アミノアクリジンで
ある特許請求の範囲第1項記載の抗菌剤徐放性導
尿カテーテル。 6 アクリジン化合物が3,6−ジアミノアクリ
ジンである特許請求の範囲第1項記載の抗菌剤徐
放性導尿カテーテル。 7 アクリジン化合物が6,9−ジアミノ−2−
エトキシアクリジンである特許請求の範囲第1項
記載の抗菌剤徐放性導尿カテーテル。[Claims] 1. A urinary catheter mainly composed of an organic polymer elastomer, characterized in that a poorly water-soluble acridine compound or a salt thereof is dispersed in the matrix of the organic polymer elastomer. Antibacterial sustained release urinary catheter. 2. The antibacterial agent sustained release urinary catheter according to claim 1, wherein a thin coating layer made only of an organic polymer elastomer is provided on the outer surface and/or the inner surface of the urinary catheter. 3. The antibacterial agent sustained release urinary catheter according to claim 1, wherein a layer consisting only of an organic polymer elastomer is provided between the outer surface and the inner surface of the urinary catheter. 4. The antibacterial agent sustained release urinary catheter according to claim 1, wherein the organic polymer elastomer is natural rubber or silicone rubber. 5. The antibacterial agent sustained release urinary catheter according to claim 1, wherein the acridine compound is 9-aminoacridine. 6. The antibacterial agent sustained release urinary catheter according to claim 1, wherein the acridine compound is 3,6-diaminoacridine. 7 The acridine compound is 6,9-diamino-2-
The antibacterial agent sustained release urinary catheter according to claim 1, which is ethoxyacridine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58148454A JPS6040061A (en) | 1983-08-12 | 1983-08-12 | Antibacterial agent slow releasing urine guide catheter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58148454A JPS6040061A (en) | 1983-08-12 | 1983-08-12 | Antibacterial agent slow releasing urine guide catheter |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6040061A JPS6040061A (en) | 1985-03-02 |
JPH0328224B2 true JPH0328224B2 (en) | 1991-04-18 |
Family
ID=15453128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58148454A Granted JPS6040061A (en) | 1983-08-12 | 1983-08-12 | Antibacterial agent slow releasing urine guide catheter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6040061A (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6080457A (en) * | 1983-10-07 | 1985-05-08 | ユニチカ株式会社 | Antibacterial agent slow releasing urethral catheter |
US20040052928A1 (en) | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
KR101215821B1 (en) | 2003-06-30 | 2012-12-28 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
JP4917889B2 (en) | 2003-09-25 | 2012-04-18 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | Compositions for treating amyloid-related diseases and methods of use thereof |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US7732479B2 (en) | 2004-08-19 | 2010-06-08 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
US7786086B2 (en) | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
AR083885A1 (en) | 2010-11-15 | 2013-03-27 | Univ Ramot | ANALOGS OF DIPEPTIDES FOR THE TREATMENT OF AFFECTIONS ASSOCIATED WITH THE FORMATION OF AMILOID FIBRILLES |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5883971A (en) * | 1981-11-13 | 1983-05-19 | ユニチカ株式会社 | Production of urine guide cathetel having capacity preventing infection of urinal tract |
-
1983
- 1983-08-12 JP JP58148454A patent/JPS6040061A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5883971A (en) * | 1981-11-13 | 1983-05-19 | ユニチカ株式会社 | Production of urine guide cathetel having capacity preventing infection of urinal tract |
Also Published As
Publication number | Publication date |
---|---|
JPS6040061A (en) | 1985-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4675347A (en) | Antimicrobial latex composition | |
US20190343991A1 (en) | Multi-layered Device | |
EP0379271B1 (en) | Anti-infective and lubricious medical articles and method for their preparation | |
US8062691B2 (en) | Method for treating medical devices using glycerol and an antimicrobial agent | |
JPH0261261B2 (en) | ||
Jansen et al. | In-vitro efficacy of a central venous catheter (‘Hydrocath’) loaded with teicoplanin to prevent bacterial colonization | |
EP2754413B1 (en) | Medical devices containing nitroprusside and antimicrobial agents | |
HUT74669A (en) | Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections | |
JPH0328224B2 (en) | ||
KR20090012250A (en) | Silicone Elastomers Containing Preservatives | |
JP5393030B2 (en) | Medical device and method for manufacturing medical device | |
DE10242476B4 (en) | Antibiotic / antibiotics-polymer combination | |
US20090076480A1 (en) | Active Ingredient-Containing Silicone Elastomers | |
Park et al. | PDMS-based polyurethanes with MPEG grafts: Mechanical properties, bacterial repellency, and release behavior of rifampicin | |
JPH0310341B2 (en) | ||
JPH0364143B2 (en) | ||
JPH0474026B2 (en) | ||
KR102548671B1 (en) | Antimicrobial compositions comprising antimicrobial hydrogels effective against mature biofilms | |
JPS62161377A (en) | Medical tool gradually releasing antibacterial agent | |
JPH032551B2 (en) | ||
JPH036822B2 (en) |